3/3
08:00 am
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
High
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2/27
08:00 am
bmea
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
Medium
Report
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
1/14
08:02 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/13
09:00 am
bmea
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
High
Report
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
1/10
08:03 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
Medium
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
1/7
09:00 am
bmea
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Low
Report
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
1/6
07:00 am
bmea
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/17
09:23 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
Medium
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
12/17
08:10 am
bmea
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
High
Report
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
12/16
06:19 pm
bmea
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) [Yahoo! Finance]
High
Report
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) [Yahoo! Finance]
12/16
06:15 pm
bmea
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
High
Report
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
12/16
08:06 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
12/12
05:02 pm
bmea
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Low
Report
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)